Viral Hepatitis Management
During hepatitis infection a high calorie diet is required along with moderate physical activity. The important step in the management of hepatitis is the intake of correct drug with correct dosage and frequency. Hepatitis A does not progress into chronic condition and hence the management requires supportive treatment such as intravenous administration of fluid and nutrition. In most cases hepatitis B results into chronic state and hence drug treatment is mandatory. The drugs used for the treatment of hepatitis B include interferon alpha, Pegylated interferon, Lamivudine, Adefovir dipivoxi, Telbivudine and Tenofovir. The drugs used in the management of hepatitis C include telaprevir, boceprevir, dasabuvir. The treatment of hepatitis D is difficult and lacks specific anti-viral drugs. The management of Hepatitis E includes bed rest along with supplementation of proper nutrition.
Related Conference of Viral Hepatitis Management
5th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
17th International Conference on Chronic Obstructive Pulmonary Disease
Viral Hepatitis Management Conference Speakers
Recommended Sessions
- Advancement in New Drug Discovery for Treatment of Hepatitis
- Critical Care and Hepatology Nursing
- Epidemiology of Hepatitis
- Hepatitis Care
- Hepatocellular Carcinoma
- Intestinal Rehabilitation
- Liver Cancer
- Liver Diseases Diagnosis
- Liver Fibrosis
- Liver Transplantation and Surgery
- Molecular Biology of Hepatitis A, B, C, D and E Viruses
- Pancreatic Diseases
- Pathophysiology of Hepatitis
- Pediatric Gastroenterology, Hepatology and Nutrition
- Pregnancy and Liver Diseases
- Recent Advances in the Viral Hepatitis C Treatment
- Types of Hepatitis
- Viral Hepatitis Management
Related Journals
Are you interested in
- Advances in Tuberculosis Diagnosis, Treatment, and Prevention - Tuberculosis-2025 (France)
- Asthma - Pulmonary Meet 2025 (France)
- Asthma and COPD - COPD_2025 (Spain)
- Chronic Bronchitis - Pulmonary Meet 2025 (France)
- Chronic Obstructive Pulmonary Disease - COPD_2025 (Spain)
- Co-Morbidities of COPD - COPD_2025 (Spain)
- Community-based Approaches to TB and Lung Health Awareness - Tuberculosis-2025 (France)
- COPD - Pulmonary Meet 2025 (France)
- COPD and Cardiovascular Diseases - COPD_2025 (Spain)
- COPD Complications - COPD_2025 (Spain)
- COPD Exacerbations - COPD_2025 (Spain)
- COPD Pathogenesis - COPD_2025 (Spain)
- COPD Therapeutics - COPD_2025 (Spain)
- COPD: Sign and Symptoms - COPD_2025 (Spain)
- Cystic Fibrosis - Pulmonary Meet 2025 (France)
- Depression and anxiety in COPD - COPD_2025 (Spain)
- Digital Health Technologies for Respiratory Disease Management - Tuberculosis-2025 (France)
- Drug Discovery of COPD - COPD_2025 (Spain)
- Early Diagnosis and Biomarkers in Respiratory Diseases - Tuberculosis-2025 (France)
- Emerging Respiratory Threats and Pandemic Preparedness - Tuberculosis-2025 (France)
- Emphysema - Pulmonary Meet 2025 (France)
- Epidemiology of COPD - COPD_2025 (Spain)
- Genetic risk factor of COPD - COPD_2025 (Spain)
- Genetics and Susceptibility to Tuberculosis and Lung Diseases - Tuberculosis-2025 (France)
- Global Efforts to Eliminate Tuberculosis by 2030 - Tuberculosis-2025 (France)
- Hospital-acquired Infections and Respiratory Care - Tuberculosis-2025 (France)
- Impact of Smoking and Environmental Factors on Lung Health - Tuberculosis-2025 (France)
- Infectious Respiratory Diseases - Pulmonary Meet 2025 (France)
- Interstitial lung disease - Pulmonary Meet 2025 (France)
- Latent Tuberculosis: Diagnosis, Treatment, and Control - Tuberculosis-2025 (France)
- Lung cancer - COPD_2025 (Spain)
- Lung Cancer - Pulmonary Meet 2025 (France)
- Lung Health: Emerging Trends and Challenges - Tuberculosis-2025 (France)
- Lung problems - Pulmonary Meet 2025 (France)
- Lung transplantation - Pulmonary Meet 2025 (France)
- Multidrug-Resistant Tuberculosis (MDR-TB) and Novel Therapies - Tuberculosis-2025 (France)
- Neonatal and Maternal Respiratory Health - Tuberculosis-2025 (France)
- Novel Therapies and Drug Development for Tuberculosis - Tuberculosis-2025 (France)
- Pathophysiology of COPD - COPD_2025 (Spain)
- Pediatric Pulmonary, Critical care and Sleep - COPD_2025 (Spain)
- Pediatric Tuberculosis and Respiratory Health - Tuberculosis-2025 (France)
- Pleural Diseases - Pulmonary Meet 2025 (France)
- Prevention and Control of Respiratory disease - Pulmonary Meet 2025 (France)
- Pulmonary diseases-treatment and therapies - COPD_2025 (Spain)
- Pulmonary Hypertension - Pulmonary Meet 2025 (France)
- Pulmonary Hypertension - COPD_2025 (Spain)
- Pulmonary Rehabilitation - Pulmonary Meet 2025 (France)
- Pulmonary Rehabilitation and Holistic Care for Respiratory Diseases - Tuberculosis-2025 (France)
- Pulmonary vascular disease - Pulmonary Meet 2025 (France)
- Pulmonology - Pulmonary Meet 2025 (France)
- Respiratory Disorders - Pulmonary Meet 2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Tract Infections - Pulmonary Meet 2025 (France)
- Role of Artificial Intelligence in Tuberculosis Diagnosis - Tuberculosis-2025 (France)
- Self-Management and Prevention of COPD - COPD_2025 (Spain)
- Sleep-Related Respiratory Disorders - Pulmonary Meet 2025 (France)
- Tuberculosis - Pulmonary Meet 2025 (France)
- Tuberculosis and HIV Co-infection: Challenges and Treatment - Tuberculosis-2025 (France)
- Tuberculosis Prevention and Global Public Health Strategies - Tuberculosis-2025 (France)
- Types of COPD - COPD_2025 (Spain)